Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Barrios

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
NPJ Breast Cancer|April 29, 2023
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
The Lancet. Oncology|May 31, 2026
Cancer workforce-a global crisis: a Lancet Oncology CommissionHedvig Hricak, Zachary J Ward, Fabio Ynoe Moraes, et al.
NPJ Breast Cancer|January 5, 2021
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
BMC Cancer|January 5, 2019
PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114)Gustavo Werutsky, Bruno Hochhegger, José Antônio Lopes de Figueiredo Pinto, et al.
Therapeutic Advances in Medical Oncology|June 5, 2023
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy Dennis J Slamon, Peter A Fasching, Sara Hurvitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerA Gennari, F André, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trialS Delaloge, D Cella, Y Ye, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
NPJ Breast Cancer|April 29, 2023
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
The Lancet. Oncology|May 31, 2026
Cancer workforce-a global crisis: a Lancet Oncology CommissionHedvig Hricak, Zachary J Ward, Fabio Ynoe Moraes, et al.
NPJ Breast Cancer|January 5, 2021
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
BMC Cancer|January 5, 2019
PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114)Gustavo Werutsky, Bruno Hochhegger, José Antônio Lopes de Figueiredo Pinto, et al.
Therapeutic Advances in Medical Oncology|June 5, 2023
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy Dennis J Slamon, Peter A Fasching, Sara Hurvitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerA Gennari, F André, C H Barrios, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trialS Delaloge, D Cella, Y Ye, et al.
Pageof 19